A C-type single-domain antibody with protective efficacy against H1N1 via respiratory administration

Abstract

Keywords:
• H1N1
• , Hemagglutinin
• , C-type single-domain antibody (C-sdAb)
• , Respiratory delivery

References

1. Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, Ronneberger O, Willmore L, Ballard AJ, Bambrick J, Bodenstein SW, Evans DA, Hung C-C, O'Neill M, Reiman D, Tunyasuvunakool K, Wu Z, Zemgulyte A, Arvaniti E, Beattie C, Bertolli O, Bridgland A, Cherepanov A, Congreve M, Cowen-Rivers AI, Cowie A, Figurnov M, Fuchs FB, Gladman H, Jain R, Khan YA, Low CMR, Perlin K, Potapenko A, Savy P, Singh S, Stecula A, Thillaisundaram A, Tong C, Yakneen S, Zhong ED, Zielinski M, Zidek A, Bapst V, Kohli P, Jaderberg M, Hassabis D, Jumper JM. 2024. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature, 630: 493-500.
   

2. An L, Liu R, Tang W, Wu J-G, Chen X. 2014. Screening and identification of inhibitors against influenza A virus from a US drug collection of 1280 drugs. Antiviral Research, 109: 54-63.
   

3. Bloom JD, Gong LI, Baltimore D. 2010. Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance. Science, 328: 1272-1275.
   

4. Boonstra S, Blijleven JS, Roos WH, Onck PR, van der Giessen E, van Oijen AM. 2018. Hemagglutinin-Mediated Membrane Fusion: A Biophysical Perspective. Annual Review of Biophysics, 47: 153-173.
   

5. Cao G, Gao X, Zhan Y, Wang Q, Zhang Z, Dimitrov DS, Gong R. 2020. An engineered human IgG1 CH2 domain with decreased aggregation and nonspecific binding. MAbs, 12: 1689027.
   

6. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JPM, Skehel JJ, Lanzavecchia A. 2011. A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins. Science, 333: 850-856.
   

7. Cunningham S, Piedra PA, Martinon-Torres F, Szymanski H, Brackeva B, Dombrecht E, Detalle L, Fleurinck C, Cunningham S, Piedra PA, Verhulst S, Matthijs I, Proesmans M, Goetghebuer T, Bosheva M, Dosev S, Nikolova O, Chakarova P, Wu Hupat E, Mesa Monsalve J, Turkalj M, Mesaric Antoncic N, Tesovic G, Sipl M, Kljaic Bukvic B, Ivkovic-Jurekovic I, Cicak B, Skalova S, Horneff G, Vogelberg C, Gacs E, Kalocsai K, Madarasi A, Kovacs L, Novak Z, Bene Z, Ashkenazi S, Goldbart A, Bentur L, Kolosa N, Gardovska D, Khaw PG, Toh TH, De Bruyne JA, Tan KK, Alberto E, Sablan BJ, de Leon A, Szymanski H, Repko M, Kralinsky K, Salamanca de la Cueva I, Rodrigo Gonzalo de Liria C, Martinon-Torres F, Cedena Romero MP, Monteagudo Montesinos E, Teeratakulpisarn J, Puthanakit T, Oberdorfer P, Warachit B, Brackeva B, Dombrecht E, Detalle L, Fleurinck C. 2021. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. The Lancet Respiratory Medicine, 9: 21-32.
   

8. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJWM, Geelen E, Sahin O, Sieuwerts M, Brakenhoff JPJ, Vogels R, Li OTW, Poon LLM, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RHE. 2012. Highly Conserved Protective Epitopes on Influenza B Viruses. Science, 337: 1343-1348.
   

9. Erbelding EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, Paules CI, Graham BS, Fauci AS. 2018. A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. The Journal of Infectious Diseases, 218: 347-354.
   

10. Gong R, Chen W, Dimitrov DS. 2012a. Expression, Purification, and Characterization of Engineered Antibody CH2 and VH Domains. In: Therapeutic Proteins: Methods and Protocols, Voynov V and Caravella JA eds.). Totowa, NJ: Humana Press, pp. 85-102.
    

11. Gong R, Wang Y, Ying T, Dimitrov DS. 2012b. Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn. PLoS One, 7: e42288.
    

12. Gong R, Wang Y, Ying T, Feng Y, Streaker E, Prabakaran P, Dimitrov DS. 2013. N-terminal truncation of an isolated human IgG1 CH2 domain significantly increases its stability and aggregation resistance. Mol Pharm, 10: 2642-2652.
    

13. Guthmiller JJ, Han J, Utset HA, Li L, Lan LY-L, Henry C, Stamper CT, McMahon M, O'Dell G, Fernandez-Quintero ML, Freyn AW, Amanat F, Stovicek O, Gentles L, Richey ST, de la Pena AT, Rosado V, Dugan HL, Zheng N-Y, Tepora ME, Bitar DJ, Changrob S, Strohmeier S, Huang M, Garcia-Sastre A, Liedl KR, Bloom JD, Nachbagauer R, Palese P, Krammer F, Coughlan L, Ward AB, Wilson PC. 2022. Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature, 602: 314-320.
    

14. Hayden FG, Sugaya N, Hirotsu N, Lee N, Jong MDd, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A. 2018. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. New England Journal of Medicine, 379: 913-923.
    

15. Holliger P, Hudson PJ. 2005. Engineered antibody fragments and the rise of single domains. Nat Biotechnol, 23: 1126-1136.
    

16. Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, Hayden FG, Hui DS, Hungnes O, Lackenby A, Lim W, Meijer A, Penn C, Tashiro M, Uyeki TM, Zambon M. 2012. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. The Lancet Infectious Diseases, 12: 240-248.
    

17. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ, Wu P, Kyncl J, Ang LW, Park M, Redlberger-Fritz M, Yu H, Espenhain L, Krishnan A, Emukule G, van Asten L, Pereira da Silva S, Aungkulanon S, Buchholz U, Widdowson M-A, Bresee JS, Azziz-Baumgartner E, Cheng P-Y, Dawood F, Foppa I, Olsen S, Haber M, Jeffers C, MacIntyre CR, Newall AT, Wood JG, Kundi M, Popow-Kraupp T, Ahmed M, Rahman M, Marinho F, Sotomayor Proschle CV, Vergara Mallegas N, Luzhao F, Sa L, Barbosa-Ramirez J, Sanchez DM, Gomez LA, Vargas XB, Acosta Herrera a, Llanes MJ, Fischer TK, Krause TG, Moelbak K, Nielsen J, Trebbien R, Bruno A, Ojeda J, Ramos H, an der Heiden M, del Carmen Castillo Signor L, Serrano CE, Bhardwaj R, Chadha M, Narayan V, Kosen S, Bromberg M, Glatman-Freedman A, Kaufman Z, Arima Y, Oishi K, Chaves S, Nyawanda B, Al-Jarallah RA, Kuri-Morales PA, Matus CR, Corona MEJ, Burmaa A, Darmaa O, Obtel M, Cherkaoui I, van den Wijngaard CC, van der Hoek W, Baker M, Bandaranayake D, Bissielo A, Huang S, Lopez L, Newbern C, Flem E, Groeneng GM, Hauge S, de Cosio FG, de Molto Y, Castillo LM, Cabello MA, von Horoch M, Medina Osis J, Machado A, Nunes B, Rodrigues AP, Rodrigues E, Calomfirescu C, Lupulescu E, Popescu R, Popovici O, Bogdanovic D, Kostic M, Lazarevic K, Milosevic Z, Tiodorovic B, Chen M, Cutter J, Lee V, Lin R, Ma S, Cohen AL, Treurnicht F, Kim WJ, Delgado-Sanz C, de mateo Ontanon S, Larrauri A, Leon IL, Vallejo F, Born R, Junker C, Koch D, Chuang J-H, Huang W-T, Kuo H-W, Tsai Y-C, Bundhamcharoen K, Chittaganpitch M, Green HK, Pebody R, Goni N, Chiparelli H, Brammer L, Mustaquim D. 2018. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. The Lancet, 391: 1285-1300.
    

18. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Zidek A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie A, Romera-Paredes B, Nikolov S, Jain R, Adler J, Back T, Petersen S, Reiman D, Clancy E, Zielinski M, Steinegger M, Pacholska M, Berghammer T, Bodenstein S, Silver D, Vinyals O, Senior AW, Kavukcuoglu K, Kohli P, Hassabis D. 2021. Highly accurate protein structure prediction with AlphaFold. Nature, 596: 583-589.
    

19. Kallewaard NL, Corti D, Collins PJ, Neu U, McAuliffe JM, Benjamin E, Wachter-Rosati L, Palmer-Hill FJ, Yuan AQ, Walker PA, Vorlaender MK, Bianchi S, Guarino B, De Marco A, Vanzetta F, Agatic G, Foglierini M, Pinna D, Fernandez-Rodriguez B, Fruehwirth A, Silacci C, Ogrodowicz RW, Martin SR, Sallusto F, Suzich JA, Lanzavecchia A, Zhu Q, Gamblin SJ, Skehel JJ. 2016. Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes. Cell, 166: 596-608.
    

20. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. The Lancet, 364: 759-765.
    

21. Kondo N, Miyauchi K, Meng F, Iwamoto A, Matsuda Z. 2010. Conformational Changes of the HIV-1 Envelope Protein during Membrane Fusion Are Inhibited by the Replacement of Its Membrane-spanning Domain *. Journal of Biological Chemistry, 285: 14681-14688.
    

22. Krissinel E, Henrick K. 2007. Inference of Macromolecular Assemblies from Crystalline State. Journal of Molecular Biology, 372: 774-797.
    

23. Larios Mora A, Detalle L, Gallup JM, Van Geelen A, Stohr T, Duprez L, Ackermann MR. 2018. Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs. mAbs, 10: 778-795.
    

24. Laursen NS, Friesen RHE, Zhu X, Jongeneelen M, Blokland S, Vermond J, van Eijgen A, Tang C, van Diepen H, Obmolova G, van der Neut Kolfschoten M, Zuijdgeest D, Straetemans R, Hoffman RMB, Nieusma T, Pallesen J, Turner HL, Bernard SM, Ward AB, Luo J, Poon LLM, Tretiakova AP, Wilson JM, Limberis MP, Vogels R, Brandenburg B, Kolkman JA, Wilson IA. 2018. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science, 362: 598-602.
    

25. Li M, Zhan Y, Wu B, Qin Y, Gao J, Liu L, Gong R. 2025. Comparison of C-type Nanoantibody Produced in Different Expression Systems Implying Potential Clinical Applications. Molecular Pharmaceutics, 22: 387-396.
    

26. Lim JJ, Dar S, Venter D, Horcajada JP, Kulkarni P, Nguyen A, McBride JM, Deng R, Galanter J, Chu T, Newton EM, Tavel JA, Peck MC, investigators obotN. 2021. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection. Open Forum Infectious Diseases, 9.
    

27. Moscona A. 2009. Global Transmission of Oseltamivir-Resistant Influenza. New England Journal of Medicine, 360: 953-956.
    

28. Nambulli S, Xiang Y, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WB, Reed DS, Crossland NA, Shi Y, Duprex WP. 2021. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Sci Adv, 7, eabh0319.
    

29. Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, Kawaguchi K, Uehara T, Shishido T, Naito A, Cusack S. 2018. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Scientific Reports, 8: 9633.
    

30. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases, 12: 36-44.
    

31. Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE. 2021. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Science, 30: 70-82.
    

32. Pezzulo AA, Tang XX, Hoegger MJ, Abou Alaiwa MH, Ramachandran S, Moninger TO, Karp PH, Wohlford-Lenane CL, Haagsman HP, van Eijk M, Banfi B, Horswill AR, Stoltz DA, McCray PB, Welsh MJ, Zabner J. 2012. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature, 487: 109-113.
    

33. Skehel JJ, Wiley DC. 2000. Receptor Binding and Membrane Fusion in Virus Entry: The Influenza Hemagglutinin. Annual Review of Biochemistry, 69: 531-569.
    

34. Sloan SE, Szretter KJ, Sundaresh B, Narayan KM, Smith PF, Skurnik D, Bedard S, Trevejo JM, Oldach D, Shriver Z. 2020. Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study. Antiviral Research, 184: 104763.
    

35. Su Y, Yang H, Zhang B, Qi X, Tien P. 2008. A dual reporter gene based system to quantitate the cell fusion of avian influenza virus H5N1. Biotechnology Letters, 30: 73-79.
    

36. Sun X, Ma H, Wang X, Bao Z, Tang S, Yi C, Sun B. 2024. Broadly neutralizing antibodies to combat influenza virus infection. Antiviral Research, 221: 105785.
    

37. Wang R, Zhang H, Peng C, Shi J, Zhang H, Gong R. 2021. Identification and Characterization of a Novel Single Domain Antibody Against Ebola Virus. Virologica Sinica, 36: 1600-1610.
    

38. Wei C-J, Crank MC, Shiver J, Graham BS, Mascola JR, Nabel GJ. 2020. Next-generation influenza vaccines: opportunities and challenges. Nature Reviews Drug Discovery, 19: 239-252.
    

39. Wooliscroft B. 2008. The Great Influenza: The Story of the Deadliest Pandemic in History, By John M. Barry, Penguin Books, USA, 2005 (revised edn), ISBN 0-14-30-3649-1. Journal of Public Affairs, 8: 217-218.
    

40. Xiang Y, Nambulli S, Xiao Z, Liu H, Sang Z, Duprex WP, Schneidman-Duhovny D, Zhang C, Shi Y. 2020. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science, 370: 1479-1484.
    

41. Zajac M, Dreano E, Edwards A, Planelles G, Sermet-Gaudelus I. 2021. Airway Surface Liquid pH Regulation in Airway Epithelium Current Understandings and Gaps in Knowledge. International Journal of Molecular Sciences, 22: 3384.
    

42. Zhang L, Shao Y, Zou X, Cui Y, Ding S, Chen Y, Wu Q, Mu S, Li X, Yang Q, Cao B, Deng T. 2025. A primary oseltamivir-resistant mutation in influenza hemagglutinin and its implications for antiviral resistance surveillance. Nature Communications, 16: 11442.
    

43. Zhang M-Y, Shu Y, Rudolph D, Prabakaran P, Labrijn AF, Zwick MB, Lal RB, Dimitrov DS. 2004. Improved Breadth and Potency of an HIV-1-Neutralizing Human Single-chain Antibody by Random Mutagenesis and Sequential Antigen Panning. Journal of Molecular Biology, 335: 209-219.
    

Proportional views